MedTrace Logo

Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients

NCT01523652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2012-02-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether HGF serum concentration might be raised in vivo by administering nadroparin given with prophylactic purpose to gynecological patients.

Conditions

  • Genital Diseases, Female
  • Ovarian Neoplasms
  • Urogenital Neoplasms

Sponsors & Collaborators

  • University of Turin, Italy

    collaborator OTHER

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Paolo Zola, MD · University of Turin, Italy

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Completion
2008-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01523652 on ClinicalTrials.gov